feburic对痛风有效果没？

feburic (febuxostat) is a new non-purine xanthine oxidase (XO) selective inhibitor approved for marketing. It can reduce blood urate concentration and is currently a new drug in the treatment of gout. Because of its remarkable efficacy and safety, it has been widely used in clinical research.

The starting doses of feburic can be 40mg/day and 80mg/day, with the 80mg dose being more effective for severe patients. If the serum uric acid level is still higher than 6 mg/dL after taking 40 mg/day for 2 weeks, you can take 80 mg/day.

Is feburic effective against gout?

The safety and efficacy of feburic (febuxostat) in gout were evaluated based on a multi-center, double-blind, randomized phase II clinical study. A total of 136 men and 17 women with gout were randomized to receive placebo or feburic (40, 80 or 120 mg/d).

After 4 weeks, the test found that the serum uric acid concentration of patients in each dose group of feburic (febuxostat) was significantly lower than before treatment. According to the dose, each group decreased by an average of 37%, 44% and 59% respectively, while the placebo group only decreased by 2%.

The vast majority of patients persisted in completing the trial. The incidence of adverse reactions in the feburic and placebo groups was similar, and most of these adverse reactions were mild and self-limiting. Common ones included diarrhea, pain, back pain, headache and joint pain.

The "Chinese Gout Diagnosis and Treatment Guidelines (2016)" recommends that gout patients can use allopurinol (2B) or feburic (febuxostat) (2B) to inhibit uric acid production, but feburic has more advantages than allopurinol in terms of effectiveness and safety. The uric acid-lowering effect of feburic 40 mg/day is similar to that of allopurinol 300 mg/day.

The above is an introduction to the effect of feburic in treating gout. If you have other related questions, please consult the medical companion passenger service.